Selected research
Industry Research
Radionuclide Drug Conjugate(RDC) Industry Research Report 2026
Market perspective
The global Radionuclide Drug Conjugate(RDC) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Radionuclide Drug Conjugate(RDC) market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Radionuclide Drug Conjugate(RDC) market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Radionuclide Drug Conjugate(RDC) market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Radionuclide Drug Conjugate(RDC) include China Tongfang Pharmaceuticals, Zhihe Biotechnology, Yuanda Pharmaceuticals, Novartis, Kelun Biotech, Hengrui, Fulian Pharmaceuticals, Dongcheng Pharmaceuticals and Bayer, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Radionuclide Drug Conjugate(RDC) market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Radionuclide Drug Conjugate(RDC).
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Radionuclide Drug Conjugate(RDC) Market by Company
China Tongfang Pharmaceuticals
Zhihe Biotechnology
Yuanda Pharmaceuticals
Novartis
Kelun Biotech
Hengrui
Fulian Pharmaceuticals
Dongcheng Pharmaceuticals
Bayer
Telix Pharmaceuticals
Lantheus
Curium
Radionuclide Drug Conjugate(RDC) Segment by Type
Therapy
Diagnosis
Radionuclide Drug Conjugate(RDC) Segment by Application
Prostate Cancer
Neuroendocrine Cancer
Other
Radionuclide Drug Conjugate(RDC) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radionuclide Drug Conjugate(RDC) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radionuclide Drug Conjugate(RDC) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radionuclide Drug Conjugate(RDC).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Radionuclide Drug Conjugate(RDC) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Therapy
- Diagnosis
Applications
- Prostate Cancer
- Neuroendocrine Cancer
- Other
Companies covered
- China Tongfang Pharmaceuticals
- Zhihe Biotechnology
- Yuanda Pharmaceuticals
- Novartis
- Kelun Biotech
- Hengrui
- Fulian Pharmaceuticals
- Dongcheng Pharmaceuticals
- Bayer
- Telix Pharmaceuticals
- Lantheus
- Curium
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Radionuclide Drug Conjugate(RDC) by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Therapy
- 2.2.3 Diagnosis
- 2.3 Radionuclide Drug Conjugate(RDC) by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Prostate Cancer
- 2.3.3 Neuroendocrine Cancer
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Radionuclide Drug Conjugate(RDC) Breakdown Data by Type
- 3.1 Global Radionuclide Drug Conjugate(RDC) Historic Market Size by Type (2021-2026)
- 3.2 Global Radionuclide Drug Conjugate(RDC) Forecasted Market Size by Type (2027-2032)
4 Radionuclide Drug Conjugate(RDC) Breakdown Data by Application
- 4.1 Global Radionuclide Drug Conjugate(RDC) Historic Market Size by Application (2021-2026)
- 4.2 Global Radionuclide Drug Conjugate(RDC) Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Radionuclide Drug Conjugate(RDC) Market Perspective (2021-2032)
- 5.2 Global Radionuclide Drug Conjugate(RDC) Growth Trends by Region
- 5.2.1 Global Radionuclide Drug Conjugate(RDC) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Radionuclide Drug Conjugate(RDC) Historic Market Size by Region (2021-2026)
- 5.2.3 Radionuclide Drug Conjugate(RDC) Forecasted Market Size by Region (2027-2032)
- 5.3 Radionuclide Drug Conjugate(RDC) Market Dynamics
- 5.3.1 Radionuclide Drug Conjugate(RDC) Industry Trends
- 5.3.2 Radionuclide Drug Conjugate(RDC) Market Drivers
- 5.3.3 Radionuclide Drug Conjugate(RDC) Market Challenges
- 5.3.4 Radionuclide Drug Conjugate(RDC) Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Radionuclide Drug Conjugate(RDC) Players by Revenue
- 6.1.1 Global Top Radionuclide Drug Conjugate(RDC) Players by Revenue (2021-2026)
- 6.1.2 Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Players (2021-2026)
- 6.2 Global Radionuclide Drug Conjugate(RDC) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Radionuclide Drug Conjugate(RDC) Head Office and Area Served
- 6.4 Global Radionuclide Drug Conjugate(RDC) Players, Product Type & Application
- 6.5 Global Radionuclide Drug Conjugate(RDC) Manufacturers Established Date
- 6.6 Global Radionuclide Drug Conjugate(RDC) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Radionuclide Drug Conjugate(RDC) Market Size (2021-2032)
- 7.2 North America Radionuclide Drug Conjugate(RDC) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Radionuclide Drug Conjugate(RDC) Market Size by Country (2021-2026)
- 7.4 North America Radionuclide Drug Conjugate(RDC) Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Radionuclide Drug Conjugate(RDC) Market Size (2021-2032)
- 8.2 Europe Radionuclide Drug Conjugate(RDC) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Radionuclide Drug Conjugate(RDC) Market Size by Country (2021-2026)
- 8.4 Europe Radionuclide Drug Conjugate(RDC) Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size (2021-2032)
- 9.2 Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Radionuclide Drug Conjugate(RDC) Market Size (2021-2032)
- 10.2 South America Radionuclide Drug Conjugate(RDC) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Radionuclide Drug Conjugate(RDC) Market Size by Country (2021-2026)
- 10.4 South America Radionuclide Drug Conjugate(RDC) Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size (2021-2032)
- 11.2 Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 China Tongfang Pharmaceuticals
- 12.1.1 China Tongfang Pharmaceuticals Company Information
- 12.1.2 China Tongfang Pharmaceuticals Business Overview
- 12.1.3 China Tongfang Pharmaceuticals Revenue in Radionuclide Drug Conjugate(RDC) Business (2021-2026)
- 12.1.4 China Tongfang Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
- 12.1.5 China Tongfang Pharmaceuticals Recent Developments
- 12.2 Zhihe Biotechnology
- 12.2.1 Zhihe Biotechnology Company Information
- 12.2.2 Zhihe Biotechnology Business Overview
- 12.2.3 Zhihe Biotechnology Revenue in Radionuclide Drug Conjugate(RDC) Business (2021-2026)
- 12.2.4 Zhihe Biotechnology Radionuclide Drug Conjugate(RDC) Product Portfolio
- 12.2.5 Zhihe Biotechnology Recent Developments
- 12.3 Yuanda Pharmaceuticals
- 12.3.1 Yuanda Pharmaceuticals Company Information
- 12.3.2 Yuanda Pharmaceuticals Business Overview
- 12.3.3 Yuanda Pharmaceuticals Revenue in Radionuclide Drug Conjugate(RDC) Business (2021-2026)
- 12.3.4 Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
- 12.3.5 Yuanda Pharmaceuticals Recent Developments
- 12.4 Novartis
- 12.4.1 Novartis Company Information
- 12.4.2 Novartis Business Overview
- 12.4.3 Novartis Revenue in Radionuclide Drug Conjugate(RDC) Business (2021-2026)
- 12.4.4 Novartis Radionuclide Drug Conjugate(RDC) Product Portfolio
- 12.4.5 Novartis Recent Developments
- 12.5 Kelun Biotech
- 12.5.1 Kelun Biotech Company Information
- 12.5.2 Kelun Biotech Business Overview
- 12.5.3 Kelun Biotech Revenue in Radionuclide Drug Conjugate(RDC) Business (2021-2026)
- 12.5.4 Kelun Biotech Radionuclide Drug Conjugate(RDC) Product Portfolio
- 12.5.5 Kelun Biotech Recent Developments
- 12.6 Hengrui
- 12.6.1 Hengrui Company Information
- 12.6.2 Hengrui Business Overview
- 12.6.3 Hengrui Revenue in Radionuclide Drug Conjugate(RDC) Business (2021-2026)
- 12.6.4 Hengrui Radionuclide Drug Conjugate(RDC) Product Portfolio
- 12.6.5 Hengrui Recent Developments
- 12.7 Fulian Pharmaceuticals
- 12.7.1 Fulian Pharmaceuticals Company Information
- 12.7.2 Fulian Pharmaceuticals Business Overview
- 12.7.3 Fulian Pharmaceuticals Revenue in Radionuclide Drug Conjugate(RDC) Business (2021-2026)
- 12.7.4 Fulian Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
- 12.7.5 Fulian Pharmaceuticals Recent Developments
- 12.8 Dongcheng Pharmaceuticals
- 12.8.1 Dongcheng Pharmaceuticals Company Information
- 12.8.2 Dongcheng Pharmaceuticals Business Overview
- 12.8.3 Dongcheng Pharmaceuticals Revenue in Radionuclide Drug Conjugate(RDC) Business (2021-2026)
- 12.8.4 Dongcheng Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
- 12.8.5 Dongcheng Pharmaceuticals Recent Developments
- 12.9 Bayer
- 12.9.1 Bayer Company Information
- 12.9.2 Bayer Business Overview
- 12.9.3 Bayer Revenue in Radionuclide Drug Conjugate(RDC) Business (2021-2026)
- 12.9.4 Bayer Radionuclide Drug Conjugate(RDC) Product Portfolio
- 12.9.5 Bayer Recent Developments
- 12.10 Telix Pharmaceuticals
- 12.10.1 Telix Pharmaceuticals Company Information
- 12.10.2 Telix Pharmaceuticals Business Overview
- 12.10.3 Telix Pharmaceuticals Revenue in Radionuclide Drug Conjugate(RDC) Business (2021-2026)
- 12.10.4 Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
- 12.10.5 Telix Pharmaceuticals Recent Developments
- 12.11 Lantheus
- 12.11.1 Lantheus Company Information
- 12.11.2 Lantheus Business Overview
- 12.11.3 Lantheus Revenue in Radionuclide Drug Conjugate(RDC) Business (2021-2026)
- 12.11.4 Lantheus Radionuclide Drug Conjugate(RDC) Product Portfolio
- 12.11.5 Lantheus Recent Developments
- 12.12 Curium
- 12.12.1 Curium Company Information
- 12.12.2 Curium Business Overview
- 12.12.3 Curium Revenue in Radionuclide Drug Conjugate(RDC) Business (2021-2026)
- 12.12.4 Curium Radionuclide Drug Conjugate(RDC) Product Portfolio
- 12.12.5 Curium Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst